

BMJ Open Impact of carbapenem resistance on mortality in patients infected with *Enterobacteriaceae*: a systematic review and meta-analysis

Ruyin Zhou ¹, Xiangming Fang,^{1,2} Jinjin Zhang,¹ Xiaodong Zheng,³ Shuangyue Shangguan,¹ Shibo Chen,⁴ Yingbo Shen,⁵ Zhihai Liu,⁶ Juan Li,⁷ Rong Zhang,⁸ Jianzhong Shen,⁹ Timothy R Walsh,¹⁰ Yang Wang⁹

To cite: Zhou R, Fang X, Zhang J, *et al*. Impact of carbapenem resistance on mortality in patients infected with *Enterobacteriaceae*: a systematic review and meta-analysis. *BMJ Open* 2021;**11**:e054971. doi:10.1136/bmjopen-2021-054971

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2021-054971>).

Received 29 June 2021
Accepted 22 November 2021



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to
Xiangming Fang;
xmfang@cau.edu.cn

ABSTRACT

Objectives To provide a comprehensive assessment of the impact of carbapenem resistance on mortality among patients infected with *Enterobacteriaceae* and to explore the source of heterogeneity across studies.

Design This systematic review was conducted following the guidelines of Cochrane Guidance and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

Data sources We conducted a systematic literature search of the PubMed, Embase, Web of Science and Cochrane Library databases to identify relevant studies published between 1 January 1994 and 30 August 2020.

Eligibility criteria We included primary observational studies published in English that reported the mortality outcomes for hospitalised patients with confirmed infections due to carbapenem-resistant *Enterobacteriaceae* (CRE) and carbapenem-susceptible *Enterobacteriaceae* (CSE). Studies with no comparison group or with a comparison group of patients infected with unconfirmed CSE were excluded.

Data extraction and synthesis Data extraction and assessment of risk bias were conducted independently by two reviewers. The pooled relative risk and risk difference were calculated as effect measures with 95% CIs using a random effects model. The heterogeneity across studies was assessed by Q-statistic and I² measures.

Results Of 10304 studies initially identified, 50 studies were included in the meta-analyses. The results of the meta-analyses showed that carbapenem resistance has a significant positive effect on the probability of death for patients infected with *Enterobacteriaceae* for any type of mortality outcome. The results of the stratified analysis and meta-regression suggested that the effect of carbapenem resistance on the risk of death varied by infection type, sample size and year of publication.

Conclusions Our results suggested that patients with CRE infection still face a greater risk of death than patients with CSE infection do, and an urgent need to develop new antibiotics and appropriate treatments to reduce the risk of death.

PROSPERO registration number CRD42020176808.

INTRODUCTION

The *Enterobacteriaceae* species, mainly *Klebsiella pneumoniae* and *Escherichia coli*, can cause infections like bloodstream infections,

Strengths and limitations of this study

- This study provided a comprehensive meta-analysis to assess the impact of carbapenem resistance on mortality among patients infected with *Enterobacteriaceae*, including nearly 20 new published studies in the last 3 years that were not included in previous relevant reviews.
- The statistical test and meta-regression analysis in this study were conducted for different groups of mortality outcome type, which may help to address the potential heterogeneity caused by the factor of mortality measurements.
- This review is the first to explore the source of heterogeneity across studies through meta-regression analysis and to consider the country's economic status and geographical region in assessing the association between carbapenem resistance and mortality among patients infected with *Enterobacteriaceae*.
- This review includes effect measures in both relative and absolute terms, thus providing a complete picture of the effect of carbapenem resistance on mortality among patients infected with *Enterobacteriaceae*.
- The comparison in our research is currently limited to high-income and upper middle-income countries from the Americas, Asia and Europe due to insufficient data from elsewhere; more studies from different countries, especially low-income countries and other regions, are needed to provide comprehensive data for further analysis stratified by geographical region and economic status.

ventilator-associated pneumonia, intra-abdominal infections and urinary tract infections in both healthcare and community settings.¹ The treatment of these infections is becoming increasingly challenging because of the increasing prevalence of multidrug-resistant *Enterobacteriaceae*, such as extended-spectrum β -lactamases (ESBLs)-producing *Enterobacteriaceae*. To counter this challenge, carbapenems were introduced in the 1980s²



and proved efficacious in the clinical treatment of infections caused by ESBLs-producing *Enterobacteriaceae*.³ However, since the carbapenem-resistant *Enterobacteriaceae* (CRE) emerged in the early 1990s,⁴ CRE has been increasingly reported worldwide.^{5 6} The prevalence of CRE is driven primarily by the spread of carbapenemases, a group of β -lactamases hydrolysing carbapenems.⁷ The CRE strains that produce diverse types of carbapenemases are endemic in different areas of the world.⁸ Countries that have high overall rates of CRE include Greece, Italy, Brazil, China, the USA and Colombia.⁷ For example, the rate of carbapenem resistance in *Klebsiella pneumoniae* isolates was as high as 63.9% in Greece in 2018.⁹ The increasing prevalence of CRE has posed a serious threat to public health because of the reduced efficacy of carbapenem and limited available therapy options, so CRE has been categorised as the most critical group of multidrug-resistant pathogens with the most urgent need for new antibiotics.¹⁰

The mortality of CRE infections is a research hotspot. Recently, some systematic reviews have included meta-analyses to assess the association between CRE infections and mortality by comparing with the mortality outcome of patients infected with carbapenem-susceptible *Enterobacteriaceae* (CSE).^{11–16} The results showed that CRE infections could lead to increased mortality. The latest systematic review on this topic included studies published until 2017,¹² but nearly 20 relevant articles have been published since then. A timely and comprehensive summary of the results of these articles can help explain the excess health burden that is attributable to CRE infections. Moreover, although previous systematic reviews have identified heterogeneity across studies and discussed some confounding factors of mortality, including patient-related, infection-related, organism-related and therapy-related factors,^{12 13 15} few used a formal statistical approach or meta-regression analysis to examine whether the effect of carbapenem resistance on mortality varies by these factors. In addition, these earlier reviews have not considered differences in economic status and geographical region. The development of antibiotic resistance has resulted in decreasing effectiveness of first-line antibiotics, such that more expensive second-line and third-line antibiotic treatments must be used. However, these treatments may be unobtainable or unaffordable for patients with resistant infections in developing countries,¹⁷ which would result in worse prognostic outcomes. The effect of carbapenem resistance on mortality may have regional differences because the CRE strains with different types of carbapenemases and virulence characteristics¹ are predominant in different regions worldwide.⁸ Two previous reviews have shown that the mortality rate of patients with CRE infections differs by geographical region.^{14 18} However, without data from patients with CSE infections, whether the impact of carbapenem resistance on mortality differs between the region will remain unknown.

Therefore, we aim to provide a comprehensive systematic review of the impact of carbapenem resistance on

mortality among patients infected with *Enterobacteriaceae* and explore the source of heterogeneity among studies to help policymakers to develop strategies and policies to combat CRE worldwide.

METHODS

This systematic review was conducted following the guidelines of Cochrane Guidance¹⁹ and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.²⁰ The protocol was registered with PROSPERO on 5 July 2020. The initial protocol was designed with a broad scope, but we divided our work into two parts to limit its length: the first (this study) focuses on mortality and the second will focus on morbidity and the economic outcomes.

Search strategy

We conducted a systematic literature search of the databases of PubMed, Embase, Web of Science and the Cochrane Library for relevant studies published between 1 January 1994 and 30 August 2020 to identify eligible studies. This period was chosen because CRE were first reported in the 1990s. Specifically, the strains producing metallo- β -lactamase imipenemase 1 (IMP-1), which is a type of carbapenemase that can hydrolyse carbapenems, were first identified in Japan in a study published in 1994.⁴

The search strategy was designed by combining the terms for bacteria and carbapenem resistance (see online supplemental appendix 1). The search terms for the bacteria were '*Enterobacteriaceae*', along with '*Klebsiella pneumoniae*' and '*Escherichia coli*', (the two most clinically important pathogens within the *Enterobacteriaceae* family). The search terms for carbapenem resistance were 'carbapenem-resistant', 'carbapenem resistance', 'carbapenem non-susceptible' and 'carbapenemase-producing' because CRE can be generally divided into carbapenemase-producing CRE (CP-CRE) and non-CP-CRE.²¹

Selection criteria

We included studies that fulfilled all of the following criteria: (1) primary observational studies (ie, case-control study, cohort study), (2) studies published between 1 January 1994 and 30 August 2020, (3) studies published in English and (4) studies that assessed the mortality of hospitalised patients with confirmed infections due to CRE and CSE.

Studies that met any of the following criteria were excluded: (1) studies that could not provide the mortality data for patients with confirmed CRE infection, (2) studies that focused on the resistance of other antibiotics instead of carbapenem antibiotics, (3) studies with no comparison group or with a comparison group of patients infected with unconfirmed CSE, (4) studies on animals or (5) publications like editorials and letters. The list of excluded studies with reasons for exclusion is provided in online supplemental appendix 2.

Two reviewers independently screened all titles and abstracts of the initially identified studies and then reviewed the full text of studies that met all of the inclusion criteria and none of the exclusion criteria. Disagreements were resolved through consensus or discussion with a third senior reviewer.

Data extraction

Data were extracted from each selected study into a data extraction form in Excel. The extracted data included the first author, year of publication, study period, country, region, country income level classified by the World Bank,²² study design, infection type, specific pathogen, sample size and the number of deaths in CRE and CSE groups. Notably, we assigned the income status of the country based on the period when the study was conducted because the income status of some countries may have changed between 1994 and 2020. For example, there were 15 studies conducted in China between 2006 and 2018 included in this meta-analysis, but since the income status of China changed from the lower income level to the upper income level in 2010, the two studies conducted between 2006 and 2009 were classified as lower middle income, and the other 13 studies conducted after 2010 were classified as upper middle income. The kinds of measurements of mortality outcomes that were extracted from included studies were all-cause in-hospital mortality, all-cause mortality at 6–30 days (6 days, 7 days, 14 days, 21 days, 28 days, 30 days) after diagnosis, mortality in ICU, 30-day mortality in ICU and mortality attributable to infection, which is usually defined as the death of a patient with clinical and laboratory evidence of ongoing infection in the absence of other feasible reasons.

Data extraction was conducted by two reviewers independently and disagreements were resolved through consensus or discussion with a third senior reviewer.

Data synthesis and analysis

We calculated the pooled relative risk (RR) and risk difference (RD) by comparing the mortality of patients with CRE infection with that of patients with CSE infection. RR was chosen as the relative measure rather than the OR because the latter was more difficult to interpret than RR^{23 24} and was usually misinterpreted as RR, which may overestimate the intervention effect when RR is more than 1.²⁵ We also calculated RD to describe the absolute difference in the risk of mortality between the two groups because reporting only the RR may conceal the underlying absolute risks, resulting in readers' overestimating the effect.²⁶ It has been recommended that both RR and absolute risk should be reported to provide a complete picture of the effect.²⁷ We calculated the pooled estimates of RRs and RDs with 95% CIs were calculated using a random effects model based on the method of DerSimonian and Laird,²⁸ with the estimate of heterogeneity being taken from the Mantel-Haenszel model. An RR of 1 and an RD of 0 indicate that the risk of mortality is identical regardless of carbapenem resistance. When

RR >1 or RD >0, it means carbapenem resistance has a positive effect on the risk of death for patients infected with *Enterobacteriaceae*; in other words, the risk of death from CRE infection is higher than that from CSE infection. The heterogeneity across studies was assessed by Q-statistic and I² measures. The heterogeneity was considered substantial when I² >50%.

In the primary analysis, we calculated the pooled estimates of the overall mortality using one mortality outcome in each study with a priority given to in-hospital mortality and the latest time point of mortality if mortality outcomes at multiple time points were reported in a study. Then, we categorised the mortality measurements into eight groups and conducted meta-analysis for each type of mortality outcome. In further analysis, to identify the potential sources of heterogeneity, we conducted stratified analysis by bacterial species, geographical region, economic status, source of infection, sample size and resistance mechanism in the mortality outcome groups, in which substantial heterogeneity was detected. An F test based on a one-way analysis of variance was used to test the differences in the mean effect estimates between subgroups. In the groups of mortality outcome type with more than ten studies, we also conducted the random-effects meta-regression analyses. The meta-regression analysis was based on restricted maximum likelihood using an iterative procedure to determine whether the effect estimates differ significantly by the above variables, and p<0.1 was considered statistically significant. A sensitivity analysis was conducted for the overall mortality, with the pooled RRs recalculated using random effects meta-analysis after removing one study at a time to evaluate the stability of the results. Finally, we conducted a funnel plot for the overall mortality to assess the publication bias. All the statistical analyses were conducted using the Stata V.15 software.

Risk of bias assessment

Two reviewers independently assessed the risk of bias for each included study using the Newcastle-Ottawa quality assessment scale (NOS) for observational studies,²⁹ and disagreements were resolved through consensus or discussion with a third senior reviewer.

Patient and public involvement

Patients and the public were not involved in the design, or conduct, or reporting or dissemination plans of this systematic review.

RESULTS

We identified 10 304 studies from the literature search, among which 50 studies^{30–79} were selected for final review based on the inclusion and exclusion criteria (figure 1). The basic characteristics of the included studies are provided in table 1, and online supplemental table 1 shows the details of the studies. The studies were conducted in 14 countries from four regions. Nearly half




Figure 1 Flowchart of the study selection process for the meta-analysis. CRE, carbapenem-resistant *Enterobacteriaceae*.

of the studies were conducted in Asia (n=24), followed by the Americas (n=15) and Europe (n=9), with only one study conducted in Africa. We also included a multi-region study that contained data from Asia, Africa and South America.⁷⁹ Most of the studies were conducted in high-income countries (n=27) and upper middle-income countries (n=19), only three studies were conducted in lower middle-income countries and no study conducted in a low-income country met the criteria. Most studies (n=39) reported mortality outcomes of infections that were due to *Klebsiella pneumoniae* pathogens, while two studies reported mortality outcomes of infections that were due to *E. coli*, and nine studies reported mortality outcomes regardless of the specific species of *Enterobacteriaceae*. Nearly half of the studies (n=24) evaluated infected patients regardless of specific infection type. Among the studies that focused on specific sites of infection, bloodstream infection was the most frequent type (n=21), followed by urinary tract infection (n=3), and one study each for neurosurgical infection and pneumonia. Among the 50 studies included, most were cohort studies (n=29). In the other 21 case-control studies, the mortality outcomes were measured using a cohort study design, so these studies were assessed as cohort studies in our quality appraisal. The NOS assessment for the risk of bias of all included studies was summarised in online supplemental appendix 4. According to the NOS scores, 46 were categorised as having a low risk of bias (scoring 7 to 9) and only four studies were categorised as having the moderate risk of bias (scoring 4 to 6).

Meta-analysis results

Among the 50 studies included, 10 different measures of mortality were reported. In-hospital mortality (n=31) was

most frequently reported, followed by 28-day mortality (n=9), 30-day mortality (n=8), mortality attributable to infection (n=8), 14-day mortality (n=4) and mortality in ICU (n=4). The mortality rates that were not commonly reported were 7-day mortality (n=2), 6-day mortality (n=1), 21-day mortality (n=1) and 30-day mortality in the ICU (n=1). The meta-analysis result for the overall mortality based on the measure of RR (RR, 2.14, 95% CI 1.85 to 2.48; $I^2=80.0\%$) (figure 2) and RD (RD, 0.22, 95% CI 0.18 to 0.26; $I^2=78.0\%$) (figure 3) suggested that carbapenem resistance was associated with increased risk of overall mortality, although a high level of heterogeneity was detected in these results.

The results of meta-analyses for different mortality outcome types showed that the I^2 for the pooled RR and RD was 0 in the studies that reported 14-day mortality, 6-day or 7-day mortality and mortality in ICU, demonstrating low heterogeneity (table 2). Among these three groups, the lowest pooled RR (1.17, 95% CI 1.08 to 1.28) and RD (0.09, 95% CI 0.04 to 0.14) was from the studies that reported mortality in the ICU. Although the pooled RR for 6-day or 7-day mortality (RR, 3.68, 95% CI 2.32 to 5.83) was higher than that for 14-day mortality (RR, 1.70, 95% CI 1.24 to 2.35), the pooled RD for both groups was 0.18. However, substantial heterogeneity was detected in the groups of studies that reported in-hospital mortality, 28-day or 30-day mortality, or mortality that was attributable to infection, which suggests other sources of heterogeneity.

Stratified analysis

To explore the source of heterogeneity between studies, we conducted a stratified analysis for each type of mortality outcome that had substantial heterogeneity. The potential sources of heterogeneity we explored were pathogens, geographical region, economic status of the country, source of infection, resistance mechanism type, sample size and publication year. One study⁷⁹ was not included in our subgroup analysis by geographical region and country income level, because it was conducted in 10 countries with different economic status from three continents.

For in-hospital mortality, carbapenem resistance had a significant positive effect on the risk of death for patients infected with *Enterobacteriaceae* in most subgroups. However, in-hospital mortality was not significantly different in either relative or absolute terms between CRE infection and CSE infection in studies that focused on patients infected with *E. coli* pathogens (RR, 3.83, 95% CI 0.46 to 31.78, p=0.214; RD, 0.27, 95% CI -0.06 to 0.59, p=0.115) or oxacillinase (OXA)-producing *Enterobacteriaceae* (RR, 3.15, 95% CI 0.45 to 21.96, p=0.247; RD, 0.24, 95% CI -0.05 to 0.53, p=0.110). In addition, no significant difference in pooled RR for in-hospital mortality was observed in studies that focused on patients with urinary tract infections (RR, 2.40, 95% CI 0.82 to 7.03, p=0.110). The statistical test based on RR and RD showed that the effect of carbapenem resistance on mortality was not

Table 1 Characteristics of included studies

First author (year)	Study period	Country	Infection type	Pathogen	Mortality outcomes
Alicino (2015) ³⁰	2007.1–2014.12	Italy	BSI	<i>K.pneumoniae</i>	30-day mortality
Balkhair (2019) ³¹	2007.1–2016.12	Oman	BSI	<i>K.pneumoniae</i>	30-day mortality
Ben-David (2012) ³²	2006.1–2006.12	Israel	BSI	<i>K.pneumoniae</i>	In-hospital mortality, mortality attributable to infection
Brizendine (2015) ³³	2006–2012	USA	UTI	<i>K.pneumoniae</i>	In-hospital mortality
Chang (2019) ³⁴	2014.1–2018.7	China	BSI	<i>K.pneumoniae</i>	7-day mortality, 28-day mortality, In-hospital mortality
Chang (2011) ³⁵	2006.1–2008.12	China	BSI	<i>E.coli</i>	14-day mortality, 28-day mortality, In-hospital mortality
Chiotos (2018) ³⁶	2011.1–2016.7	USA	Mixed	<i>Enterobacteriaceae</i>	30-day mortality
Cienfuegos-Gallet (2019) ³⁷	2014.2–3; 2014.10–2015.9	Colombia	Mixed	<i>K.pneumoniae</i>	30-day mortality
Correa (2013) ³⁸	2006.1–2008.8	Brazil	Mixed	<i>K.pneumoniae</i>	In-hospital mortality
Cubero (2015) ³⁹	2010.10–2012.12	Spain	Mixed	<i>K.pneumoniae</i>	In-hospital mortality
Daikos (2009) ⁴⁰	2004.2–2006.3	Greece	BSI	<i>K.pneumoniae</i>	14-day mortality
Fraenkel-Wandel (2016) ⁴¹	2006–2012	Israel	BSI	<i>K.pneumoniae</i>	In-hospital mortality
Gallagher (2014) ⁴²	2005.6–2010.10	USA	BSI	<i>K.pneumoniae</i>	In-hospital mortality
Garbati (2016) ⁴³	2012.3–2013.12	Saudi Arabia	Mixed	<i>Enterobacteriaceae</i>	In-hospital mortality
Gomez Rueda (2014) ⁴⁴	2008.1–2011.1	Colombia	Mixed	<i>K.pneumoniae</i>	In-hospital mortality
Hoxha (2016) ⁴⁵	2012.11–2013.7	Italy	Mixed	<i>K.pneumoniae</i>	6-day mortality, 30-day mortality
Huang (2018) ⁴⁶	2017.1–2017.12	China	Mixed	<i>K.pneumoniae</i>	In-hospital mortality
Hussein (2013) ⁴⁷	2006.1–2008.12	Israel	BSI	<i>K.pneumoniae</i>	30-day mortality
Kotb (2020) ⁴⁸	2011–2017	Egypt	Mixed	<i>Enterobacteriaceae</i>	Mortality in ICU
Lee (2016) ⁴⁹	2013.1–2014.2	Korea	Mixed	<i>Enterobacteriaceae</i>	28-day mortality, In-hospital mortality
Li (2019) ⁵⁰	2014.1–2018.6	China	Mixed	<i>K.pneumoniae</i>	30-day mortality in ICU
Liu (2019) ⁵¹	2014.1–2018.9	China	BSI	<i>K.pneumoniae</i>	30-day mortality
Liu (2012) ⁵²	2007.1–2009.12	China	BSI	<i>K.pneumoniae</i>	14-day mortality, 28-day mortality, In-hospital mortality
Mclaughlin (2014) ⁵³	2010.3–2011.12	USA	BSI	<i>K.pneumoniae</i>	In-hospital mortality
Meng (2017) ⁵⁴	2012.1–2015.12	China	Mixed	<i>E. coli</i>	In-hospital mortality
Mouloudi (2010) ⁵⁵	2007.1–2008.12	Greece	BSI	<i>K.pneumoniae</i>	In-hospital mortality, mortality in ICU, mortality attributable to infection
Ny (2015) ⁵⁶	2011.1–2013.12	USA	Mixed	<i>K.pneumoniae</i>	In-hospital mortality
Orsi (2013) ⁵⁷	2008.7–2011.6	Italy	Mixed	<i>K.pneumoniae</i>	In-hospital mortality
Pan (2019) ⁵⁸	2014	China	Mixed	<i>K.pneumoniae</i>	In-hospital mortality
Patel (2008) ⁵⁹	2004.7–2006.6	USA	Mixed	<i>K.pneumoniae</i>	In-hospital mortality, mortality attributable to infection
Pereira (2015) ⁶⁰	2010.1–2013.1	USA	Mixed	<i>K.pneumoniae</i>	In-hospital mortality
Pouch (2015) ⁶¹	2007.1–2010.12	USA	UTI	<i>Enterobacteriaceae</i>	In-hospital mortality
Qureshi (2012) ⁶²	2011.1–2014.12	USA	BSI	<i>K.pneumoniae</i>	28-day mortality
Sánchez-Romero (2011) ⁶³	2009.1–2009.12	Spain	Mixed	<i>K.pneumoniae</i>	14-day mortality
Schwaber (2008) ⁶⁴	2003.9–2006.12	Israel	Mixed	<i>K.pneumoniae</i>	In-hospital mortality
Shilo (2013) ⁶⁵	2006.1–2009.12	Israel	UTI	<i>K.pneumoniae</i>	In-hospital mortality
Simkins (2014) ⁶⁶	2006.1–2010.12	USA	Mixed	<i>K.pneumoniae</i>	In-hospital mortality
Tian (2016) ⁶⁷	2011.1–2015.12	China	BSI	<i>K.pneumoniae</i>	In-hospital mortality, mortality attributable to infection, 28-day mortality
Torres-Gonzalez (2016) ⁶⁸	2013.11–2015.7	Mexico	Mixed	<i>Enterobacteriaceae</i>	Mortality attributable to infection

Continued

Table 1 Continued

First author (year)	Study period	Country	Infection type	Pathogen	Mortality outcomes
Treacarich (2016) ⁶⁹	2010.1–2014.6	Italy	BSI	<i>K.pneumoniae</i>	21-day mortality
Ulu (2015) ⁷⁰	2012.1–2012.12	Turkey	Mixed	<i>K.pneumoniae</i>	Mortality in ICU
Vardakas (2015) ⁷¹	2006.1–2009.10	Greece	Mixed	<i>K.pneumoniae</i>	Mortality in ICU
Wang (2018) ⁷²	2010.1–2014.12	China	Mixed	<i>K.pneumoniae</i>	In-hospital mortality
Xiao (2018) ⁷³	2013.1–2015.12	China	BSI	<i>K.pneumoniae</i>	30-day mortality
Zhang (2018) ⁷⁴	2011.1–2014.12	China	BSI	<i>K.pneumoniae</i>	7-day mortality, 28-day mortality, In-hospital mortality
Zheng (2018) ⁷⁵	2014.1–2016.12	China	BSI	<i>K.pneumoniae</i>	28-day mortality
Zheng (2020) ⁷⁶	2012–2017	China	Neurosurgical infection	<i>Enterobacteriaceae</i>	Mortality attributable to infection
Zuo (2020) ⁷⁷	2015–2017	China	Pneumonia	<i>K.pneumoniae</i>	In-hospital mortality, mortality attributable to infection
Villegas (2016) ⁷⁸	2013.7–2014.11	7 countries	BSI	<i>Enterobacteriaceae</i>	In-hospital mortality, mortality attributable to infection
Stewardson (2019) ⁷⁹	2014.8–2015.6	10 countries	BSI	<i>Enterobacteriaceae</i>	In-hospital mortality

BSI, bloodstream infection; *E. coli*, *Escherichia*; *K.pneumoniae*, *Klebsiella pneumoniae*; UTI, urinary tract infection.

significantly different between the subgroups (online supplemental table 2).

For 28-day or 30-day mortality, the subgroup analysis showed no significant difference in the mortality for CRE and CSE infections that were due to mixed

Enterobacteriaceae pathogens (RR, 1.78, 95% CI 0.57 to 5.60, $p=0.321$; RD, 0.05, 95% CI -0.03 to 0.13, $p=0.213$). The results of the statistical tests based on RR showed that the later studies, those that were published from 2017 to 2020, reported higher RR for 28-day or 30-day mortality




Figure 2 Forest plot of overall mortality in patients with carbapenem-resistant *Enterobacteriaceae* (CRE) versus carbapenem-susceptible *Enterobacteriaceae* (CSE) infections (outcome measure=relative risk). ICU, intensive care unit.




Figure 3 Forest plot of overall mortality in patients with carbapenem-resistant *Enterobacteriaceae* (CRE) versus carbapenem-susceptible *Enterobacteriaceae* (CSE) infections (outcome measure=risk difference). ICU, intensive care unit.

for patients who were infected with CRE versus CSE ($p=0.006$) than did studies that were published earlier. The statistical test results for 28-day or 30-day mortality showed that the pooled RD in studies with fewer than 100 patients was higher than that in studies with 100–200 patients. Although the pooled RD in studies with more than 200 patients was highest, the heterogeneity in this group was high and should be interpreted with caution (online supplemental table 3).

For mortality attributable to infection, the one study conducted in Europe with a sample size of fewer than 100 has found no significant difference in the risk of death for CRE and CSE infection (RR, 1.98, 95% CI 0.61 to 6.43, $p=0.255$; RD, 0.13, 95% CI, -0.07 to 0.34, $p=0.195$), nor the study that focused on patients infected with OXA-producing *Enterobacteriaceae* (RR, 1.50, 95% CI 0.43 to 5.28, $p=0.528$; RD, 0.04, 95% CI, -0.09 to 0.17, $p=0.572$). The results of statistical tests based on RD indicated that the effect of carbapenem resistance on attributable mortality was varied by the type of infection ($p=0.075$). Patients with neurosurgical infection were at greater risk of attributable death that was due to CRE infection than other types of infection (online supplemental table 4).

Meta-regression

To further explore whether the effect of carbapenem resistance on mortality differs by the variables of pathogens,

geographical region, economic status of the country, source of infection, resistance mechanism type, sample size and publication year, we conducted the univariate meta-regression in the groups of mortality outcome type with more than 10 studies. The meta-regression results based on RD showed that the effect of carbapenem resistance on mortality was not influenced significantly by all the variables (online supplemental table 5, 6). However, in terms of RR, the meta-regression for in-hospital mortality suggested that the influence of carbapenem resistance on in-hospital mortality in studies published between 2017 and 2020 was significantly greater than that in studies published between 2011 and 2013 (coefficient=-0.447, $p=0.027$) and in studies published from 2014 to 2016 (coefficient=-0.343, $p=0.061$) (online supplemental table 7). The results of the meta-regression for 28-day or 30-day mortality based on RR were similar to the results for in-hospital mortality. Moreover, the effect of carbapenem resistance on mortality at 28-day or 30-day tends to increase with the year of publication (coefficient=-0.0001, $p=0.006$) (online supplemental table 8).

Sensitivity analysis

To assess the influence of individual studies on the results, we performed a sensitivity analysis by removing one study at a time and recalculated the pooled RRs of the overall mortality among the remaining studies using



Table 2 Pooled estimated results for different types of mortality outcome

Mortality outcome type	Number of studies	Number of CRE patients	Number of CSE patients	Unweighted means of mortality among CRE patients	Unweighted means of mortality among CSE patients	RR (95% CI)	P value (significance tests of RR=1)	I ² (%)	RD (95% CI)	P value (significance tests of RD=0)	I ² (%)
In-hospital mortality	31	1668	3753	42.30%	20.00%	2.09 (1.81 to 2.42)	0.000	49.8	0.21 (0.17 to 0.26)	0.000	71.0
28-day or 30-day mortality	17	1161	2463	42.85%	19.88%	2.23 (1.83 to 2.72)	0.000	63.6	0.23 (0.15 to 0.30)	0.000	79.1
21-day mortality	1	161	117	52.20%	14.50%	3.59 (2.26 to 5.71)	0.000	-	0.38 (0.28 to 0.48)	0.000	-
14-day mortality	4	84	287	45.09%	27.01%	1.70 (1.24 to 2.35)	0.001	0.0	0.18 (0.06 to 0.31)	0.003	0.0
6-day or 7-day mortality	3	149	372	25.90%	6.57%	3.68 (2.32 to 5.83)	0.000	0.0	0.18 (0.11 to 0.26)	0.000	0.0
Mortality attributable to infection	8	391	778	43.30%	17.45%	2.74 (1.97 to 3.81)	0.000	58.3	0.27 (0.15 to 0.38)	0.000	79.5
Mortality in ICU	4	1035	824	58.83%	50.50%	1.17 (1.08 to 1.28)	0.000	0.0	0.09 (0.04 to 0.14)	0.000	0.0
30-day mortality in ICU	1	244	263	28.90%	11.00%	2.60 (1.75 to 3.87)	0.000	-	0.18 (0.11 to 0.25)	0.000	-

CRE, carbapenem-resistant *Enterobacteriaceae*; CSE, carbapenem-susceptible *Enterobacteriaceae*; ICU, intensive care unit.




Figure 4 Funnel plot of studies evaluating mortality of patients with infections due to carbapenem-resistant compared with carbapenem-susceptible *Enterobacteriaceae*.

random effects meta-analysis. We found that the direction of the effect did not change when any one study was excluded, which indicates the stability of the results of the meta-analysis.

Publication bias

Publication bias was assessed by a funnel plot (figure 4). Slight asymmetry was observed in the funnel plots and the points were heavily distributed at the top right, implying a lack of smaller studies that showed a negative association between carbapenem resistance and mortality.

DISCUSSION

This study systematically reviewed 50 studies and provides a comprehensive analysis of the impact of carbapenem resistance on mortality among patients infected with *Enterobacteriaceae*. Our analysis suggests that, for any type of mortality outcome, carbapenem resistance was associated with a greater probability of death for patients infected with CRE than that for patients infected with CSE. The results are consistent with the direction of previous meta-analyses of the association between carbapenem resistance and mortality among patients infected with *Enterobacteriaceae*.^{13 14}

As for the risk factors for worse mortality outcomes in patients with CRE infections, previous studies usually explained higher mortality among patients with CRE infection as being due to patient-related, infection-related, treatment-related and organism-related factors.^{13 14 16 80} Twenty studies included in this review conducted multivariate analyses to identify the risk factors for mortality among patients infected with *Enterobacteriaceae*. After controlling for patient-related factors like age, sex, the severity of underlying illness and comorbidities, three studies^{47 51 67} found that carbapenem resistance was not associated with increased mortality risk; however, 14 studies found that carbapenem resistance remained an independent predictor of mortality. Previous studies

also considered therapeutic interventions as important risk factors for increased mortality in CRE infection, as administration of initial antibiotic therapy with in-vitro activity is more likely to be delayed in patients with CRE infection.^{32 33 40 59 62 67 74} Several studies included in this research have suggested that the effect of carbapenem resistance was probably mediated by inappropriate initial therapy.^{37 40 51} This finding was supported by a recent review of 11 studies that used a meta-regression analysis to identify a significant association between the proportion of patients who received appropriate initial antibiotic therapy and mortality.¹⁶ However, nine studies included in our review^{32 38 41 47 62 67 71 73 74} did not identify an association between early appropriate antibiotic therapy and mortality after adjustment for some confounding factors. Instead, some studies found that other treatment methods were important risk factors of mortality. For example, a recent meta-analysis including seven studies showed that monotherapy treatment was associated with significantly higher mortality than combination therapy for patients with CRE infections.¹⁴ In addition, some studies^{72 73} have suggested that other therapies, such as adjunctive therapy, tigecycline therapy and the use of aminoglycoside, may be associated with mortality among patients infected with *Klebsiella pneumoniae*. The increased mortality among patients with CRE infections might also be related to the increased virulence of carbapenemase-producing strains. Two studies included in this meta-analysis showed that isolation of the *Klebsiella pneumoniae* carbapenemase (KPC)-positive strain was a predictor of mortality among patients infected with *Klebsiella pneumoniae* independent of the appropriateness of initial treatment and patient characteristics,^{41 55} while another study⁴⁷ found that *Klebsiella pneumoniae* carbapenemase (KPC)-positive status was not associated with mortality when the virulence score was included in the multivariate analysis. As most of the included studies we reviewed did not provide the mortality outcomes after adjusting for confounding factors, the pooled-adjusted effect measures was not calculated.

To investigate the heterogeneity across the studies, we performed stratified analysis and meta-regression based on the type of mortality outcome. In terms of RR, the meta-regression analysis for in-hospital mortality showed that the effect of carbapenem resistance on in-hospital mortality was greater in studies published in 2017–2020 than it was in studies published in 2011–2013 and 2014–2016. The statistical test and meta-regression analyses for 28-day and 30-day mortality showed similar results. The increasing effect of carbapenem resistance on mortality with the publication year could be explained by the increasingly limited availability of effective antibiotics and the development of CRE against some key antibiotics, such as colistin,⁸¹ resulting in increasing difficulty in treating CRE infection. As one study showed,¹⁶ the proportion of patients with carbapenem-resistant *Klebsiella pneumoniae* who received appropriate initial antibiotic therapy did not change over time. In contrast, mortality from CSE

infection has tended to decrease in recent years, and the unweighted mean of in-hospital mortality and 28-day and 30-day mortality among CSE patients in studies conducted from 2017 to 2020 is 11.69% and 13.43%, respectively, the lowest of the studies we reviewed. This change could be due to the development of medical technology and medical treatment, which may enlarge the relative differences in mortality between CRE and CSE infections. In addition, the statistical test for mortality attributable to infection identified a significant difference between infection types, as carbapenem resistance in patients with neurosurgical infection had a significantly greater effect on mortality compared with other types of infection, perhaps because of difficulty in treating CRE meningitis/encephalitis in neurosurgery.⁷⁴ In terms of RR, the statistical test showed that, compared with studies with fewer than 100 patients, carbapenem resistance had a greater effect on 28-day and 30-day mortality in studies with 100–200 patients, indicating that the absolute RD of mortality between CRE and CSE infection tends to be more stable with larger sample size.

To our knowledge, this study offers the most comprehensive meta-analysis so far of the impact of carbapenem resistance on mortality among patients infected with *Enterobacteriaceae*. Nearly, 20 new studies published in the last 3 years have been included in our study. In addition, the meta-analysis was conducted in different groups of mortality outcomes, which may help address the potential heterogeneity caused by mortality measurements. Moreover, this review is the first to explore the source of heterogeneity among studies using statistical tests and meta-regression analyses of variables related to countries' economic status and geographical region. Moreover, this is the first review to explore the source of heterogeneity across studies using statistical tests and meta-regression analysis of potential variables and to consider the country's economic status and geographical region in assessing the association between carbapenem resistance and mortality among patients infected with *Enterobacteriaceae*.

Our study also has several limitations. First, among studies focusing on specific pathogens, we only included studies that focused on two clinically important *Enterobacteriaceae* species, *Klebsiella pneumoniae* and *Escherichia coli*. Second, we only included studies published in English. Third, we only calculated the unadjusted results, so many confounding factors, such as patients' health conditions and therapy options, were not adjusted in the analysis because of data limitations. In addition, we were unable to conduct the stratified analysis and meta-regression for all kinds of mortality measurements because of insufficient data. Finally, the comparison in our research is currently limited to high-income and upper middle-income countries from the Americas, Asia and Europe due to insufficient data.

Our findings reinforced previous results regarding the positive effect of carbapenem resistance on mortality for patients infected with *Enterobacteriaceae*. These findings implied that patients with CRE infection still face a

greater risk of death compared with patients with CSE infection. Furthermore, this study has identified an increasing effect of carbapenem resistance on mortality over time, especially for 28-day to 30-day mortality, which may reflect the difficulty of the CRE infection treatment in clinical practice and emphasise the urgent need to develop new antibiotics and appropriate treatment to reduce the death risk. Our results also suggested that patients with neurosurgical infection were at greater risk of attributable death that was due to CRE infection than other types of infection. Thus, more attention should be paid to CRE infection in patients with neurosurgery in clinical practice. In addition, no significant differences in the effect of carbapenem resistance on mortality for different geographical regions and economic status were observed in our study, which may result from the limited data. More studies from different countries, especially low-income countries, are needed to provide comprehensive data for further analysis stratified by geographical region and economic status.

CONCLUSIONS

Our results indicate that patients with CRE infection still face a greater risk of death than patients with CSE infection do, and an urgent need to develop new antibiotics and appropriate treatment to reduce the death risk. Future studies should address additional countries to provide comprehensive data and sound evidence from which to draw resources to fight CRE-related mortality and suggest the way forward to alleviate its implications.

Author affiliations

¹Department of Economics and Trade, College of Economics and Management, China Agricultural University, Beijing, China

²Department of Health Policy and Behavioral Sciences, School of Public Health, Georgia State University, Atlanta, GA, USA

³Department of Economics, School of Economics, Zhejiang Gongshang University, Hangzhou, China

⁴Department of Basic Veterinary Medicine, College of Veterinary Medicine, China Agricultural University, Beijing, China

⁵CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China

⁶Agricultural Bio-pharmaceutical Laboratory, College of Chemistry and Pharmaceutical Sciences, Qingdao Agricultural University, Qingdao, China

⁷State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, Beijing, China

⁸Clinical Laboratory Medicine, The Second Affiliated Hospital of Zhejiang University, Zhejiang University, Hangzhou, China

⁹Beijing Key Laboratory of Detection Technology for Animal-Derived Food Safety, College of Veterinary Medicine, China Agricultural University, Beijing, China

¹⁰Department of Zoology, University of Oxford, Oxford, UK

Contributors All authors were involved in the design and development of the study. The review was designed by XF, RoZ, RuZ, JL, JS, TRW and YW. The literature search in electronic databases was conducted by JZ, SS, SC and XZ. RuZ and JZ screened all studies for inclusion into the systematic review and performed the assessments of risk bias for all studies with the assistance of XZ, SS, SC and XF. RuZ and JZ performed data extraction. RuZ and JZ conducted data analysis and interpretation with assistance of XZ, SS, SC and XF. RuZ drafted the manuscript and YS, ZL, JL, RoZ, JS, TRW, YW, XF revised it critically for important intellectual content. All authors contributed to drafting and revision of the article and have

reviewed the results and approved the final version of the manuscript. The corresponding author (XF) is the guarantor and attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding This work was supported by the National Natural Science Foundation of China (NSFC) (Grant numbers 81861138051, 81861138052 and 81861138053).

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval This study does not involve human participants or animal subjects.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. Data sharing not applicable because all data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Ruyin Zhou <http://orcid.org/0000-0002-5731-5746>

REFERENCES

- Center for Disease Control and Prevention(US). Clinicians: information about CRE, 2019. Available: <https://www.cdc.gov/hai/organisms/cre/cre-clinicians.html> [Accessed 19 Dec 2020].
- Birnbaum J, Kahan FM, Kropp H, *et al*. Carbapenems, a new class of beta-lactam antibiotics. discovery and development of imipenem/ cilastatin. *Am J Med* 1985;78:3–21.
- Paterson DL, Ko W-C, Von Gottberg A, *et al*. Antibiotic therapy for *Klebsiella pneumoniae* bacteremia: implications of production of extended-spectrum beta-lactamases. *Clin Infect Dis* 2004;39:31–7.
- Osano E, Arakawa Y, Wacharotayankun R, *et al*. Molecular characterization of an enterobacterial metallo-beta-lactamase found in a clinical isolate of *Serratia marcescens* that shows imipenem resistance. *Antimicrob Agents Chemother* 1994;38:71–8.
- Lauretli L, Riccio ML, Mazzariol A, *et al*. Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a *Pseudomonas aeruginosa* clinical isolate. *Antimicrob Agents Chemother* 1999;43:1584–90.
- Yigit H, Queenan AM, Anderson GJ, *et al*. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2001;45:1151–61.
- Iovleva A, Doi Y. Carbapenem-Resistant Enterobacteriaceae. *Clin Lab Med* 2017;37:303–15.
- Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. *J Infect Dis* 2017;215:S28–36.
- European Centre for Disease Control and Prevention. Antimicrobial resistance surveillance in Europe 2018, 2019. Available: <https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2018> [Accessed 19 Dec 2020].
- World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics, 2017. Available: <https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/> [Accessed 19 Dec 2020].
- Budhram DR, Mac S, Bielecki JM, *et al*. Health outcomes attributable to carbapenemase-producing Enterobacteriaceae infections: a

- systematic review and meta-analysis. *Infect Control Hosp Epidemiol* 2020;41:37–43.
- 12 Soontaros S, Leelakanok N. Association between carbapenem-resistant Enterobacteriaceae and death: a systematic review and meta-analysis. *Am J Infect Control* 2019;47:1200–12.
 - 13 Martin A, Fahrbach K, Zhao Q, et al. Association Between Carbapenem Resistance and Mortality Among Adult, Hospitalized Patients With Serious Infections Due to *Enterobacteriaceae*: Results of a Systematic Literature Review and Meta-analysis. *Open Forum Infect Dis* 2018;5:ofy150.
 - 14 Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant *Klebsiella pneumoniae*. *Ann Clin Microbiol Antimicrob* 2017;16:18.
 - 15 Kohler PP, Volling C, Green K, et al. Carbapenem resistance, initial antibiotic therapy, and mortality in *Klebsiella pneumoniae* bacteremia: a systematic review and meta-analysis. *Infect Control Hosp Epidemiol* 2017;38:1319–28.
 - 16 Falagas ME, Tansarli GS, Karageorgopoulos DE, et al. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. *Emerg Infect Dis* 2014;20:1170–5.
 - 17 Laxminarayan R, Heymann DL. Challenges of drug resistance in the developing world. *BMJ* 2012;344:e1567.
 - 18 Ramos-Castañeda JA, Ruano-Ravina A, Barbosa-Lorenzo R, et al. Mortality due to KPC carbapenemase-producing *Klebsiella pneumoniae* infections: systematic review and meta-analysis: mortality due to KPC *Klebsiella pneumoniae* infections. *J Infect* 2018;76:438–48.
 - 19 Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. [updated March 2011]. London: Cochrane Collaboration, 2011. Available: <https://handbook-5-1.cochrane.org/> [Accessed 19 Dec 2020].
 - 20 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009;339:b2535.
 - 21 Suay-García B, Pérez-Gracia MT. Present and future of carbapenem-resistant Enterobacteriaceae (CRE) infections. *Antibiotics* 2019;8:122.
 - 22 World Bank. World bank country and lending groups [Internet]. Data, 2019. Available: <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups> [Accessed 20 Jun 2020].
 - 23 Sinclair JC, Bracken MB. Clinically useful measures of effect in binary analyses of randomized trials. *J Clin Epidemiol* 1994;47:881–9.
 - 24 Sackett DL, Deeks JJ, Altman DG. Down with odds ratios! *BMJ Evid Based Med* 1996;1:164–6.
 - 25 Schmidt CO, Kohlmann T. When to use the odds ratio or the relative risk? *Int J Public Health* 2008;53:165–7.
 - 26 Noordzij M, van Diepen M, Caskey FC, et al. Relative risk versus absolute risk: one cannot be interpreted without the other. *Nephrol Dial Transplant* 2017;32:ii13–18.
 - 27 Schulz KF, Altman DG, Moher D, et al. Consort 2010 statement: updated guidelines for reporting parallel group randomised trials. *Int J Surg* 2011;9:672–7.
 - 28 DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7:177–88.
 - 29 Wells GA, Shea B, O'Connell D. *The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses*. Ottawa: Ottawa Hospital Research Institute, 2014.
 - 30 Alicino C, Giacobbe DR, Orsi A, et al. Trends in the annual incidence of carbapenem-resistant *Klebsiella pneumoniae* bloodstream infections: a 8-year retrospective study in a large teaching hospital in northern Italy. *BMC Infect Dis* 2015;15:415.
 - 31 Balkhair A, Al-Muharmi Z, Al'Adawi B, et al. Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Klebsiella pneumoniae*: description of a decade-long trend. *Int J Infect Dis* 2019;85:10–15.
 - 32 Ben-David D, Kordevani R, Keller N, et al. Outcome of carbapenem resistant *Klebsiella pneumoniae* bloodstream infections. *Clin Microbiol Infect* 2012;18:54–60.
 - 33 Brizendine KD, Richter SS, Cober ED, et al. Carbapenem-resistant *Klebsiella pneumoniae* urinary tract infection following solid organ transplantation. *Antimicrob Agents Chemother* 2015;59:553–7.
 - 34 Chang H, Wei J, Zhou W, et al. Risk factors and mortality for patients with bloodstream infections of *Klebsiella pneumoniae* during 2014–2018: clinical impact of carbapenem resistance in a large tertiary hospital of China. *J Infect Public Health* 2020;13:784–90.
 - 35 Chang H-J, Hsu P-C, Yang C-C, et al. Risk factors and outcomes of carbapenem-nonsusceptible *Escherichia coli* bacteremia: a matched case-control study. *J Microbiol Immunol Infect* 2011;44:125–30.
 - 36 Chiotos K, Tamma PD, Flett KB, et al. Increased 30-day mortality associated with carbapenem-resistant Enterobacteriaceae in children. *Open Forum Infect Dis* 2018;5:ofy222.
 - 37 Cienfuegos-Gallet AV, Ocampo de Los Rios AM, Sierra Viana P, et al. Risk factors and survival of patients infected with carbapenem-resistant *Klebsiella pneumoniae* in a KPC endemic setting: a case-control and cohort study. *BMC Infect Dis* 2019;19:830.
 - 38 Correa L, Martino MDV, Siqueira I, et al. A hospital-based matched case-control study to identify clinical outcome and risk factors associated with carbapenem-resistant *Klebsiella pneumoniae* infection. *BMC Infect Dis* 2013;13:80.
 - 39 Cubero M, Cuervo G, Dominguez MÁ, et al. Carbapenem-resistant and carbapenem-susceptible isogenic isolates of *Klebsiella pneumoniae* ST101 causing infection in a tertiary hospital. *BMC Microbiol* 2015;15:177.
 - 40 Daikos GL, Petrikos P, Psychogiou M. Prospective observational study of the impact of VIM-1 metallo- β -lactamase on the outcome of patients with *Klebsiella pneumoniae* bloodstream infections. *Antimicrob Agents Chemother* 2009;53:1868–73.
 - 41 Fraenkel-Wandel Y, Raveh-Brawer D, Wiener-Well Y, et al. Mortality due to blaKPC *Klebsiella pneumoniae* bacteraemia. *J Antimicrob Chemother* 2016;71:1083–7.
 - 42 Gallagher JC, Kuriakose S, Haynes K, et al. Case-case-control study of patients with carbapenem-resistant and third-generation-cephalosporin-resistant *Klebsiella pneumoniae* bloodstream infections. *Antimicrob Agents Chemother* 2014;58:5732–5.
 - 43 Garbati MA, Sakkijha H, Abushaheena A. Infections due to carbapenem resistant Enterobacteriaceae among Saudi Arabian hospitalized patients: a matched case-control study. *Biomed Res Int* 2016;2016:1–9.
 - 44 Rueda G V, Zuleta Tobon JJ. Risk factors for infection with carbapenem-resistant *Klebsiella pneumoniae*: a case-case-control study. *Colomb Med* 2014;45:54–60.
 - 45 Hoxha A, Karki T, Giambi C, et al. Attributable mortality of carbapenem-resistant *Klebsiella pneumoniae* infections in a prospective matched cohort study in Italy, 2012–2013. *J Hosp Infect* 2016;92:61–6.
 - 46 Huang W, Qiao F, Zhang Y, et al. In-Hospital medical costs of infections caused by carbapenem-resistant *Klebsiella pneumoniae*. *Clin Infect Dis* 2018;67:S225–30.
 - 47 Hussein K, Raz-Pasteur A, Finkelstein R, et al. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by *Klebsiella pneumoniae*. *J Hosp Infect* 2013;83:307–13.
 - 48 Kotb S, Lyman M, Ismail G, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in Egyptian intensive care units using national healthcare-associated infections surveillance data, 2011–2017. *Antimicrob Resist Infect Control* 2020;9:2.
 - 49 Lee HJ, Choi JK, Cho SY, et al. Carbapenem-Resistant Enterobacteriaceae: prevalence and risk factors in a single community-based hospital in Korea. *Infect Chemother* 2016;48:166–73.
 - 50 Li Y, Shen H, Zhu C, et al. Carbapenem-Resistant *Klebsiella pneumoniae* infections among ICU admission patients in central China: prevalence and prediction model. *Biomed Res Int* 2019;2019:1–10.
 - 51 Liu J, Wang H, Huang Z, et al. Risk factors and outcomes for carbapenem-resistant *Klebsiella pneumoniae* bacteremia in onco-hematological patients. *J Infect Dev Ctries* 2019;13:357–64.
 - 52 Liu S-W, Chang H-J, Chia J-H, et al. Outcomes and characteristics of ertapenem-nonsusceptible *Klebsiella pneumoniae* bacteremia at a university hospital in Northern Taiwan: a matched case-control study. *J Microbiol Immunol Infect* 2012;45:113–9.
 - 53 McLaughlin MM, Advincula MR, Malczynski M, et al. Quantifying the clinical virulence of *Klebsiella pneumoniae* producing carbapenemase *Klebsiella pneumoniae* with a *Galleria mellonella* model and a pilot study to translate to patient outcomes. *BMC Infect Dis* 2014;14:31.
 - 54 Meng X, Liu S, Duan J, et al. Risk factors and medical costs for healthcare-associated carbapenem-resistant *Escherichia coli* infection among hospitalized patients in a Chinese teaching hospital. *BMC Infect Dis* 2017;17:82.
 - 55 Mouloudi E, Protonotariou E, Zagorianou A, et al. Bloodstream infections caused by metallo- β -lactamase/*Klebsiella pneumoniae* carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. *Infect Control Hosp Epidemiol* 2010;31:1250–6.
 - 56 Ny P, Nieberg P, Wong-Beringer A. Impact of carbapenem resistance on epidemiology and outcomes of nonbacteremic *Klebsiella pneumoniae* infections. *Am J Infect Control* 2015;43:1076–80.



- 57 Orsi GB, Bencardino A, Vena A, *et al.* Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant *Klebsiella pneumoniae* isolation: results of a double case-control study. *Infection* 2013;41:61–7.
- 58 Pan H, Lou Y, Zeng L, *et al.* Infections caused by carbapenemase-producing *Klebsiella pneumoniae*: microbiological characteristics and risk factors. *Microb Drug Resist* 2019;25:287–96.
- 59 Patel G, Huprikar S, Factor SH, *et al.* Outcomes of carbapenem-resistant *Klebsiella pneumoniae* infection and the impact of antimicrobial and adjunctive therapies. *Infect Control Hosp Epidemiol* 2008;29:1099–106.
- 60 Pereira MR, Scully BF, Pouch SM, *et al.* Risk factors and outcomes of carbapenem-resistant *Klebsiella pneumoniae* infections in liver transplant recipients. *Liver Transpl* 2015;21:1511–9.
- 61 Pouch SM, Kubin CJ, Satlin MJ, *et al.* Epidemiology and outcomes of carbapenem-resistant *Klebsiella pneumoniae* bacteriuria in kidney transplant recipients. *Transpl Infect Dis* 2015;17:800–9.
- 62 Qureshi ZA, Paterson DL, Peleg AY, *et al.* Clinical characteristics of bacteraemia caused by extended-spectrum β -lactamase-producing Enterobacteriaceae in the era of CTX-M-type and KPC-type β -lactamases. *Clin Microbiol Infect* 2012;18:887–93.
- 63 Sánchez-Romero I, Asensio A, Oteo J, *et al.* Nosocomial outbreak of VIM-1-producing *Klebsiella pneumoniae* isolates of multilocus sequence type 15: molecular basis, clinical risk factors, and outcome. *Antimicrob Agents Chemother* 2012;56:420–7.
- 64 Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, *et al.* Predictors of carbapenem-resistant *Klebsiella pneumoniae* acquisition among hospitalized adults and effect of acquisition on mortality. *Antimicrob Agents Chemother* 2008;52:1028–33.
- 65 Shilo S, Assous MV, Lachish T, *et al.* Risk factors for bacteriuria with carbapenem-resistant *Klebsiella pneumoniae* and its impact on mortality: a case-control study. *Infection* 2013;41:503–9.
- 66 Simkins J, Muggia V, Cohen HW, *et al.* Carbapenem-resistant *Klebsiella pneumoniae* infections in kidney transplant recipients: a case-control study. *Transpl Infect Dis* 2014;16:775–82.
- 67 Tian L, Tan R, Chen Y, *et al.* Epidemiology of *Klebsiella pneumoniae* bloodstream infections in a teaching hospital: factors related to the carbapenem resistance and patient mortality. *Antimicrob Resist Infect Control* 2016;5:48.
- 68 Torres-González P, Ortiz-Brizuela E, Cervera-Hernandez ME, *et al.* Associated factors and outcomes for OXA-232 carbapenem-resistant Enterobacteriaceae infections in a tertiary care centre in Mexico City: a case-control-control study. *Diagn Microbiol Infect Dis* 2016;86:243–8.
- 69 Trecarichi EM, Pagano L, Martino B, *et al.* Bloodstream infections caused by *Klebsiella pneumoniae* in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. *Am J Hematol* 2016;91:1076–81.
- 70 Candevir Ulu A, Kurtaran B, Inal AS, *et al.* Risk factors of carbapenem-resistant *Klebsiella pneumoniae* infection: a serious threat in ICUs. *Med Sci Monit* 2015;21:219–24.
- 71 Vardakas KZ, Matthaïou DK, Falagas ME, *et al.* Characteristics, risk factors and outcomes of carbapenem-resistant *Klebsiella pneumoniae* infections in the intensive care unit. *J Infect* 2015;70:592–9.
- 72 Wang Z, Qin R-R, Huang L, *et al.* Risk factors for carbapenem-resistant *Klebsiella pneumoniae* infection and mortality of *Klebsiella pneumoniae* infection. *Chin Med J* 2018;131:56–62.
- 73 Xiao T, Yu W, Niu T, *et al.* A retrospective, comparative analysis of risk factors and outcomes in carbapenem-susceptible and carbapenem-nonsusceptible *Klebsiella pneumoniae* bloodstream infections: tigecycline significantly increases the mortality. *Infect Drug Resist* 2018;11:595–606.
- 74 Zhang Y, Guo L-Y, Song W-Q, *et al.* Risk factors for carbapenem-resistant *K. pneumoniae* bloodstream infection and predictors of mortality in Chinese paediatric patients. *BMC Infect Dis* 2018;18:248.
- 75 Zheng S-H, Cao S-J, Xu H, *et al.* Risk factors, outcomes and genotypes of carbapenem-nonsusceptible *Klebsiella pneumoniae* bloodstream infection: a three-year retrospective study in a large tertiary hospital in Northern China. *Infect Dis* 2018;50:443–51.
- 76 Guanghui Z, Jing L, Guojun Z, *et al.* Epidemiology and risk factors of neurosurgical bacterial meningitis/encephalitis induced by carbapenem resistant Enterobacteriaceae. *J Infect Chemother* 2020;26:101–6.
- 77 Zuo Y, Zhao D, Song G, *et al.* Risk factors, molecular epidemiology, and outcomes of carbapenem-resistant *Klebsiella pneumoniae* infection for hospital-acquired pneumonia: a matched case-control study in eastern China during 2015–2017. *Microb Drug Resist* 2021;27:204–211.
- 78 Villegas MV, Pallares CJ, Escandón-Vargas K, *et al.* Characterization and clinical impact of bloodstream infection caused by carbapenemase-producing Enterobacteriaceae in seven Latin American countries. *PLoS One* 2016;11:e0154092.
- 79 Stewardson AJ, Marimuthu K, Sengupta S, *et al.* Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (Panorama): a multinational prospective cohort study. *Lancet Infect Dis* 2019;19:601–10.
- 80 Paño Pardo JR, Serrano Villar S, Ramos Ramos JC, *et al.* Infections caused by carbapenemase-producing Enterobacteriaceae: risk factors, clinical features and prognosis. *Enferm Infecc Microbiol Clin* 2014;32:41–8.
- 81 Sader HS, Castanheira M, Duncan LR, *et al.* Antimicrobial susceptibility of Enterobacteriaceae and *Pseudomonas aeruginosa* isolates from United States medical centers stratified by infection type: results from the International network for optimal resistance monitoring (inform) surveillance program, 2015–2016. *Diagn Microbiol Infect Dis* 2018;92:69–74.